MX339205B - Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. - Google Patents

Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Info

Publication number
MX339205B
MX339205B MX2012003414A MX2012003414A MX339205B MX 339205 B MX339205 B MX 339205B MX 2012003414 A MX2012003414 A MX 2012003414A MX 2012003414 A MX2012003414 A MX 2012003414A MX 339205 B MX339205 B MX 339205B
Authority
MX
Mexico
Prior art keywords
adamts13
formulations
liophilized
stabilized
liquids
Prior art date
Application number
MX2012003414A
Other languages
English (en)
Other versions
MX2012003414A (es
Inventor
Hans-Peter Schwarz
H Peter Matthiessen
Peter L Turecek
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2012003414A publication Critical patent/MX2012003414A/es
Publication of MX339205B publication Critical patent/MX339205B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a formulaciones de ADAMTS13 con propiedades mejoradas o deseables. Como tal, la invención proporciona formulaciones líquidas y liofilizadas de ADAMTS13 que son adecuadas para administración farmacéutica. Entre otros aspectos, la presente invención también proporciona métodos para tratar varias enfermedades y condiciones relacionadas con disfunción de VWF y/o ADAMTS13 en un sujeto. También la presente proporciona equipos que comprenden formulaciones de ADAMTSI3 útiles para el tratamiento de varias enfermedades y condiciones.
MX2012003414A 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. MX339205B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24435309P 2009-09-21 2009-09-21
PCT/US2010/049723 WO2011035335A2 (en) 2009-09-21 2010-09-21 Stabilized liquid and lyophilized adamts13 formulations

Publications (2)

Publication Number Publication Date
MX2012003414A MX2012003414A (es) 2012-06-19
MX339205B true MX339205B (es) 2016-05-16

Family

ID=43598388

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016005314A MX362382B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2012003414A MX339205B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2019000547A MX2019000547A (es) 2009-09-21 2012-03-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016005314A MX362382B (es) 2009-09-21 2010-09-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019000547A MX2019000547A (es) 2009-09-21 2012-03-21 Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.

Country Status (21)

Country Link
US (9) US8623352B2 (es)
EP (5) EP4218797B9 (es)
JP (2) JP5819303B2 (es)
KR (6) KR20250008986A (es)
CN (2) CN104224705B (es)
AU (1) AU2010295299B2 (es)
BR (1) BR112012006283B1 (es)
CA (1) CA2774556A1 (es)
DK (4) DK2480198T3 (es)
EA (1) EA024267B1 (es)
ES (4) ES3001509T3 (es)
FI (2) FI3834841T3 (es)
FR (1) FR24C1049I2 (es)
HR (1) HRP20160295T1 (es)
HU (1) HUE028688T2 (es)
IN (1) IN2012DN02645A (es)
MX (3) MX362382B (es)
NZ (1) NZ598839A (es)
PL (4) PL2480198T3 (es)
PT (2) PT4218797T (es)
WO (1) WO2011035335A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388529A1 (en) 2008-12-05 2018-10-17 Baxalta GmbH Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
AU2010295299B2 (en) 2009-09-21 2015-12-24 Takeda Pharmaceutical Company Limited Stabilized liquid and lyophilized ADAMTS13 formulations
DK2814514T3 (en) * 2012-02-16 2017-12-18 Atyr Pharma Inc Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases
CN103566362B (zh) * 2012-07-21 2015-07-29 复旦大学 重组adamts13在制备脑出血药物中的用途
WO2014075033A2 (en) 2012-11-09 2014-05-15 Puget Sound Blood Center Protein stabilizing factors
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
ES2847383T3 (es) 2013-03-15 2021-08-03 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
AU2015280480A1 (en) * 2014-06-26 2017-01-05 Amgen Inc. Protein formulations
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
ES2983978T3 (es) 2016-01-08 2024-10-28 Univ Kyoto Medicina que comprende ADAMTS13 como ingrediente principal
KR20230079461A (ko) 2016-08-04 2023-06-07 다케다 파머수티컬 컴패니 리미티드 급성 폐 손상 및/또는 급성 호흡 곤란 증후군에서 혈관폐색 위기의 치료, 개선 및/또는 예방을 위한 adamts13의 용도
ES2981519T3 (es) 2016-11-04 2024-10-09 Takeda Pharmaceuticals Co Formulaciones de virus adeno-asociados
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
UA125971C2 (uk) * 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
MX2020013953A (es) * 2018-07-11 2021-03-09 Takeda Pharmaceuticals Co Composiciones de virus adenoasociado (aav).
EP4037704B1 (en) 2019-10-04 2025-12-03 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
WO2021198781A2 (en) 2020-04-02 2021-10-07 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
JP2023526546A (ja) 2020-05-22 2023-06-21 武田薬品工業株式会社 コロナウイルス疾患の合併症の治療及び診断のための、ａｄａｍｔｓ１３組成物及び方法
US20230295597A1 (en) * 2020-08-13 2023-09-21 Hadasit Medical Research Services & Development Limited A disintegrin and metalloproteinase with a thrombospondin type i motif, member 13 (adamts-13) mutants, compositions and therapeutic methods thereof
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
KR20240112755A (ko) * 2023-01-11 2024-07-19 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
JP2001227510A (ja) 2000-02-15 2001-08-24 Tomoe Tech Res Co 複作動型の空気式アクチュエータ
JP3783507B2 (ja) 2000-02-16 2006-06-07 日本精工株式会社 トロイダル型無段変速機用ディスクの加工方法
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
ITPR20010055A1 (it) 2001-08-31 2003-03-03 Vetroarredo Spa Procedimento e impianto per la realizzazione di mattoni in vetro.
KR100472006B1 (ko) 2002-10-09 2005-03-10 동부아남반도체 주식회사 모스 트랜지스터 제조 방법
JP5112692B2 (ja) * 2003-07-07 2013-01-09 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル フォンビルブランド因子（ｖｗｆ）マルチマーを検出する方法およびシステム
GB0404693D0 (en) * 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL1902141T3 (pl) 2005-06-17 2012-12-31 Baxalta Inc Kompozycje o działaniu trombolitycznym zawierające ADAMTS13
JP4880997B2 (ja) * 2005-12-28 2012-02-22 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の安定化方法
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
AU2010295299B2 (en) * 2009-09-21 2015-12-24 Takeda Pharmaceutical Company Limited Stabilized liquid and lyophilized ADAMTS13 formulations
US8823352B2 (en) 2011-07-11 2014-09-02 Linear Technology Corporation Switching power supply having separate AC and DC current sensing paths

Also Published As

Publication number Publication date
ES2948612T3 (es) 2023-09-14
CN104224705B (zh) 2018-02-02
FI3834841T3 (fi) 2023-06-05
US20250099559A1 (en) 2025-03-27
US20140178357A1 (en) 2014-06-26
CN102573792A (zh) 2012-07-11
KR20180095738A (ko) 2018-08-27
DK4218797T5 (da) 2025-07-21
HUE028688T2 (en) 2017-01-30
FR24C1049I1 (fr) 2025-01-17
AU2010295299B2 (en) 2015-12-24
JP5819303B2 (ja) 2015-11-24
ES2579906T3 (es) 2016-08-17
HRP20160295T1 (hr) 2016-05-20
JP2013505270A (ja) 2013-02-14
PL3834841T3 (pl) 2023-07-24
FR24C1049I2 (fr) 2025-12-12
EP4218797A1 (en) 2023-08-02
MX362382B (es) 2019-01-14
MX2019000547A (es) 2020-11-12
EP3834841A1 (en) 2021-06-16
MX2012003414A (es) 2012-06-19
US9351935B2 (en) 2016-05-31
DK2480198T3 (en) 2016-03-29
PL4218797T3 (pl) 2025-02-10
US9572778B2 (en) 2017-02-21
WO2011035335A3 (en) 2011-12-01
KR20210054598A (ko) 2021-05-13
DK3834841T3 (da) 2023-06-06
US12178861B2 (en) 2024-12-31
PT4218797T (pt) 2024-12-09
CA2774556A1 (en) 2011-03-24
PL2480198T3 (pl) 2016-09-30
KR101891646B1 (ko) 2018-08-27
HK1173968A1 (zh) 2013-05-31
EP3167897B1 (en) 2021-01-27
EA201200519A1 (ru) 2012-09-28
EP3834841B1 (en) 2023-05-17
US20160375111A1 (en) 2016-12-29
BR112012006283B1 (pt) 2022-03-15
US10238720B2 (en) 2019-03-26
WO2011035335A2 (en) 2011-03-24
EP4218797B1 (en) 2024-09-11
EP4467160A3 (en) 2025-01-15
EP2480198A2 (en) 2012-08-01
DK3167897T3 (da) 2021-04-19
KR20250008986A (ko) 2025-01-16
EP3167897A1 (en) 2017-05-17
BR112012006283A2 (pt) 2016-05-31
CN102573792B (zh) 2014-10-15
EP2480198B9 (en) 2016-11-23
US11564979B2 (en) 2023-01-31
US10758599B2 (en) 2020-09-01
US20200376098A1 (en) 2020-12-03
PL3167897T3 (pl) 2021-09-27
KR20120099646A (ko) 2012-09-11
ES2865250T3 (es) 2021-10-15
CN104224705A (zh) 2014-12-24
EP2480198B1 (en) 2016-03-09
JP2015063556A (ja) 2015-04-09
US20180207245A1 (en) 2018-07-26
ES3001509T3 (en) 2025-03-05
KR20190137954A (ko) 2019-12-11
NZ598839A (en) 2014-03-28
DK4218797T3 (da) 2024-12-09
EA024267B1 (ru) 2016-09-30
US20190247475A1 (en) 2019-08-15
US8623352B2 (en) 2014-01-07
KR20220139456A (ko) 2022-10-14
PT3834841T (pt) 2023-06-19
US20230130866A1 (en) 2023-04-27
FI4218797T3 (fi) 2024-12-07
IN2012DN02645A (es) 2015-09-11
US20110229455A1 (en) 2011-09-22
US20170112906A1 (en) 2017-04-27
US9937244B2 (en) 2018-04-10
AU2010295299A1 (en) 2012-04-12
EP4467160A2 (en) 2024-11-27
EP4218797B9 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
MX339205B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2012001714A1 (es) Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2012003723A (es) Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
CL2014000511A1 (es) Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
MX2013004061A (es) Analogos de ciclosporina.
IN2012DN00754A (es)
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
CO7180225A2 (es) Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
IN2015DN02729A (es)
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
MX2013004062A (es) Analogos de ciclosporina.

Legal Events

Date Code Title Description
FG Grant or registration